大剂量静脉用皮质类固醇治疗眼部炎性疾病。
High-dose intravenous corticosteroids for ocular inflammatory diseases.
机构信息
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
出版信息
Ocul Immunol Inflamm. 2012 Apr;20(2):91-9. doi: 10.3109/09273948.2011.646382.
PURPOSE
To evaluate the effectiveness and risk of complications of high-dose intravenous pulsed corticosteroids for noninfectious ocular inflammatory diseases.
METHODS
Retrospective cohort study in which 104 eyes of 70 patients who received high-dose intravenous corticosteroids for treatment of active ocular inflammation were identified from five centers. The main outcome measures were control of inflammation and occurrence of ocular or systemic complications within 1 month after treatment.
RESULTS
Within ≤1 month of starting treatment, 57% of eyes achieved complete control of inflammation (95% confidence interval (CI): 33-83%), improving to 82% when near-complete control was included (95% CI: 61-96%). Most eyes (85%; 95% CI: 70-95%) gained clinically significant improvement in anterior chamber inflammation. One patient developed a colon perforation during treatment. No other major complications were recorded.
CONCLUSIONS
Treatment of ocular inflammation with high-dose intravenous corticosteroids resulted in substantial clinical improvement for most cases within 1 month. Complications of therapy were infrequent.
目的
评估大剂量静脉注射脉冲皮质类固醇治疗非传染性眼部炎症性疾病的疗效和并发症风险。
方法
回顾性队列研究，在五个中心共确定了 70 名患者的 104 只眼接受大剂量静脉皮质类固醇治疗活动性眼部炎症。主要观察指标为治疗后 1 个月内炎症控制情况和眼部或全身并发症的发生情况。
结果
治疗开始后 ≤1 个月内，57%的眼完全控制了炎症（95%置信区间：33-83%），当包括接近完全控制时，提高至 82%（95%置信区间：61-96%）。大多数眼（85%；95%置信区间：70-95%）在前房炎症方面获得了明显的临床改善。1 例患者在治疗过程中发生结肠穿孔。未记录到其他严重并发症。
结论
在 1 个月内，大剂量静脉注射皮质类固醇治疗眼部炎症使大多数病例的病情得到了显著改善。治疗并发症并不常见。
Zotero 插件